Full-Time

Scientist Structural Biology

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$108.5k - $170.5k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Boston, MA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD degree in Structural Biology, Biophysics, Biochemistry/Enzymology, Protein Chemistry or a related field with 3+ years industry experience in pharmaceutical or biotechnology structural biology role; MS with 8+ years or BS with 12+ years industry experience also considered
  • Demonstrated track record of supporting high-quality structure determination and validation of protein co-complexes to rapidly advance drug discovery pipelines
  • Experience utilizing crystallographic and modeling software package including, but not limited to, CCP4, HKL2000/3000, PHENIX, COOT, Schrodinger software, PSILO
  • Extensive knowledge of and experience in protein production including construct design/protein engineering, protein expression systems (bacterial, insect, mammalian systems), protein purification techniques and protein characterization methods
Responsibilities
  • Plan and execute gene-to-structure projects and generate target co-complex structures with small molecules and/or biologic proteins using in-house crystallization capabilities and contract research organizations
  • Analyze proprietary and public structural information to positively impact computational and medicinal chemistry efforts and/or antibody design, optimization and characterization
  • Work collaboratively on pipeline projects with an interdisciplinary team (biologists, medicinal and computational chemists, in vitro and in vivo pharmacologists, informatics scientists, DMPK, project management)
  • Utilize, support and build upon the capabilities of in-house hardware, software and database resources and engage productively with external structural biology and protein chemistry contract research organizations to achieve project and department goals
  • Clearly communicate structural data, interpretation and insights to diverse audiences including structural biology group, project teams, department colleagues and senior leadership.
Desired Qualifications
  • Experience with cryo-EM methods and structure determination, biophysical techniques (SPR, ITC, DLS, etc), crystallization automation capabilities, membrane protein production and characterization and/or CRO management is highly desirable
  • Passion for learning and advancing structural biology capabilities and drug discovery pipelines, including proactive investigation of new techniques and capabilities, advanced software and hardware and innovative experimental approaches
  • Ability to work collaboratively in a fast-paced, matrixed environment with a collaborative and proactive mindset, motivated by a desire to create therapeutic molecules for the benefit of patients in need worldwide

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized in all operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...